A Distinctive Metabolomics Pattern Associated with the Administration of Combined Sacubitril/Valsartan to Healthy Subjects: A Kinetic Approach

<b>Background/Objective:</b> Sacubitril/Valsartan are a combination drug approved for heart failure treatment, known to enhance natriuretic peptide activity and inhibit the renin–angiotensin–aldosterone system (RAAS). While its clinical efficacy is well-established, its broader impact on...

全面介紹

書目詳細資料
發表在:Pharmaceuticals
Main Authors: Randh AlAhmari, Hana M. A. Fakhoury, Reem AlMalki, Hatouf H. Sukkarieh, Lina Dahabiyeh, Tawfiq Arafat, Anas M. Abdel Rahman
格式: Article
語言:英语
出版: MDPI AG 2025-08-01
主題:
在線閱讀:https://www.mdpi.com/1424-8247/18/9/1264

相似書籍